莫莫替尼(Momelotinib Dihydrochloride) - 药物靶点：ALK2 x JAK1 x JAK2_在研适应症：原发性血小板增多症后骨髓纤维化，真性红细胞增多症后骨髓纤维化，原发性骨髓纤维化_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Momelotinib、Momelotinib dihydrochloride (USAN)、Momelotinib dihydrochloride monohydrate

+ [11]

靶点

ALK2 x JAK1 x JAK2

作用方式

抑制剂

作用机制

ALK2抑制剂(激活素受体-1抑制剂)、JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂)

治疗领域

血液及淋巴系统疾病其他疾病肿瘤

在研适应症

原发性血小板增多症后骨髓纤维化真性红细胞增多症后骨髓纤维化原发性骨髓纤维化+ [9]

非在研适应症

EGFR突变的非小细胞肺癌KRAS突变非小细胞肺癌转移性非小细胞肺癌+ [5]

原研机构

Gilead Sciences, Inc.

在研机构

GSK PlcGlaxoSmithKline LLCGlaxoSmithKline Trading Services Ltd.

+ [2]

非在研机构

Sierra Oncology, Inc.

权益机构

YM BioSciences, Inc.

Sierra Oncology, Inc.

AstraZeneca PLC

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (2023-09-15),

骨髓纤维化

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (韩国)、孤儿药 (澳大利亚)

登录后查看时间轴

结构/序列

分子式C23H26Cl2N6O3

InChIKeyRQKCPSIFARJBOR-UHFFFAOYSA-N

CAS号1841094-17-4

关联

21

项与莫莫替尼相关的临床试验

NCT06847867

/ Recruiting临床2期

A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants With Anemia Due to Low-risk Myelodysplastic Syndrome

The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. The study is comprised of two parts: Part 1: Participants will receive different doses of momelotinib to find the best dose by evaluating effectiveness in improving red blood cell transfusion requirements and safety. Part 2: Participants will receive dose selected from Part 1 to assess its impact on improving red blood cell transfusion requirements and safety in LR-MDS.

开始日期2025-06-05

申办/合作机构

GSK Plc

NCT06517875

/ Recruiting临床2期

A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis

The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.

开始日期2025-02-28

申办/合作机构

GSK Plc

NCT06235801

/ Recruiting临床1/2期IIT

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.

开始日期2024-05-22

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与莫莫替尼相关的临床结果

登录后查看更多信息

100 项与莫莫替尼相关的转化医学

登录后查看更多信息

100 项与莫莫替尼相关的专利（医药）

登录后查看更多信息

414

项与莫莫替尼相关的文献（医药）

2025-12-31·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Discovery and biological evaluation of a novel and highly potent JAK2 inhibitor for the treatment of triple negative breast cancer

Article

作者: Miao, Yingxiang ; Li, Jindong ; Zhang, Fang ; Yang, Shudan ; Zhang, Yan

Janus kinase 2 (JAK2) is considered an attractive target for the treatment of triple-negative breast cancer (TNBC). Herein, we discovered six JAK2 inhibitors using structure-based virtual screening and molecular docking. Among them, JNN-5 was the best compound. It indicated strong inhibitory effects on JAK2 in the nanomolar range (IC₅₀ = 0.41 ± 0.03 nM), and high selectivity for JAK2 over JAK1 and JAK3 (selectivity index (SI) > 73.17). Moreover, molecular dynamics (MD) simulation exhibited that JNN-5 bound with high stability to JAK2 JH1. Cellular assays revealed that JNN-5 displayed strong antiproliferative activities in the TNBC cell lines (MDA-MB-468, MDA-MB-213, HCC70, MDA-MB-157). JNN-5 significantly reduced the migration of HUVECs with the dose-dependence. JNN-5 had a significant inhibitory effect on multidrug-resistant MDA-MB-231/ADR (IC₅₀ = 0.37 ± 0.02 μM). These data demonstrate that JNN-5 may be a highly effective and selective antitumor compound for the treatment of TNBC.

2025-12-01·Current Hematologic Malignancy Reports

Emerging Therapeutic Approaches for Anemia in Myelofibrosis

Review

作者: Harrington, Patrick ; Palumbo, Giuseppe A ; Chifotides, Helen T ; Duminuco, Andrea ; Bose, Prithviraj ; Torre, Elena ; Vetro, Calogero

PURPOSE OF REVIEW:

In this review, we highlight conventional agents and novel emerging therapeutic strategies to treat anemia in MF.

RECENT FINDINGS:

Anemia is a common and challenging feature of myelofibrosis (MF). The pathobiology of anemia is multifactorial, including progressive bone marrow fibrosis, decreased erythropoiesis due to high hepcidin levels leading to iron sequestration in the reticuloendothelial system, hypersplenism, erythropoiesis inhibition by myelosuppressive JAK inhibitors (ruxolitinib, fedratinib), and others. MF-associated anemia has a negative impact on survival. Conventional agents to manage anemia include erythropoiesis-stimulating agents, danazol, corticosteroids, and immunomodulatory agents, but responses are infrequent and lack durability. Notable advancements have emerged in developing novel treatments for anemia in MF, including the regulatory approval of momelotinib (ACVR1/JAK1/2 inhibitor) in 2023 and development of novel promising agents targeting hemojuvelin and activins. Momelotinib and pacritinib (ACVR1/JAK2 inhibitor) are the preferred JAK inhibitors for patients with cytopenias (anemia, thrombocytopenia). Luspatercept and elritercept are activin receptor ligand traps, promoting erythroid maturation and late-stage erythropoiesis. Currently, luspatercept is being evaluated in a phase 3 trial (INDEPENDENCE™) for anemia in MF patients who are on a JAK2 inhibitor and require transfusions, and in a phase 2 trial (ODYSSEY) in combination with momelotinib in MF patients who are transfusion dependent, whether or not on a JAK inhibitor. Interim results of the RESTORE trial demonstrated that elritercept significantly decreased transfusions in MF patients. DISC-0974 is a first-in-class anti-hemojuvelin (positive hepcidin regulator) monoclonal antibody that decreased hepcidin expression, increased serum iron, and enhanced erythropoiesis in anemic patients with MF in a phase 1b/2 study. Burgeoning studies of novel anemia-targeted agents and combinations are significantly improving the quality of life and outcomes of patients with MF. The recent approval of momelotinib to treat MF with anemia and the emerging novel anemia-directed strategies in early and advanced clinical development have ushered in a new era in the treatment of MF-related anemia.

2025-06-03·Expert Opinion on Drug Discovery

Momelotinib – a tale of trials, tribulations, transfusion independence, and triumph

Review

作者: Vachhani, Pankit ; Desai, Ruchi J. ; Bose, Prithviraj

INTRODUCTION:

Momelotinib is a small molecule inhibitor of JAK1, JAK2, and ACVR1 that is approved by the FDA and EMA for adults patients with intermediate/high risk myelofibrosis (MF) and anemia. Inhibition of the JAK-STAT pathway has a well-established role in MF therapy, producing reductions in MF-related symptoms and spleen size. Inhibition of ACVR1 downregulates hepcidin production and improves anemia. The mechanism of action of momelotinib addresses three critical aspects of morbidity in MF, ith both spleen and symptom-directed therapy for both cytopenic and proliferative MF patients.

AREAS COVERED:

Key milestones in the development of momelotinib and its regulatory approvals are reviewed here. Additionally, the efficacy, safety, and tolerability of momelotinib are discussed. The literature review is based on a comprehensive search of English language, peer-reviewed articles using PubMed and clinical trial information is taken from w ww. ClinicalTrials.gov. Studies from 1 January 2000, through 31 January 2025, were included.

EXPERT OPINION:

The development of momelotinib represents an important breakthrough in MF therapy with spleen and symptom directed therapy with improvements in anemia and limited myelosuppression, facilitating dose intensity. Current and future research efforts for MF therapy are directed at development of newer, anemia-directed therapies including combinations with momelotinib.

165

项与莫莫替尼相关的新闻（医药）

2025-06-12

·sobi.com

Sobi share new clinical data across multiple hematologic diseases at EHA 2025

Sobi® (STO: SOBI) will present data at the 30th EHA (European Haematology Association) hybrid congress, in Milan, Italy (12-15 June). The congress will feature the latest advances in the treatment of diffuse large B-cell lymphoma (DLBCL), immune thrombocytopenia (ITP), myelofibrosis, paroxysmal nocturnal haemoglobinuria (PNH), and primary hemophagocytic lymphohistiocytosis (pHLH). An extensive programme of poster presentations will showcase Sobi’s commitment to helping patients with rare diseases by advancing treatment options. In addition, Sobi will host several scientific symposiums at the congress including: 1.Advancing Therapeutic Knowledge in Paroxysmal Nocturnal Haemoglobinuria: Reshaping disease management to unlock new norms, Thursday, 12 June, 10:00am - 11:30am CEST, at Amber Hall 3 & 4. 2. Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP), Saturday 14 June, 8.00 am - 9.30 am CEST, at Amber Hall 7 & 8. 3. Dissecting Treatment Sequencing in relapsed/refractory DLBCL, from laboratory to real life. Saturday, 14 June, 8:00 am – 9:30 am, CEST at Coral Hall 1. “The breadth of data that we share at this year’s EHA congress demonstrates Sobi’s comprehensive approach to addressing rare conditions in haematology. We are proud to contribute to advancing the science in several indications from early clinical phases in diffuse large B-cell lymphoma to clinical and real-world evidence in myelofibrosis, primary hemophagocytic lymphohistiocytosis, immune thrombocytopenia and paroxysmal nocturnal haemoglobinuria,” said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. Key data to be presented at EHA 2025 DLBCL PS1911: Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large BCell Lymphoma (DLBCL) Presenting Author: Juan Pablo Alderuccio Poster presentation Session title: Poster Session 2Session date: Saturday, 14 June Session time: 18:30-19:30 CEST Location: Poster Hall PS1957: Updated Safety Run-in Results from LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine with Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL Presenting Author: Carmelo Carlo-Stella Immune Thrombocytopenia (ITP) PF1236: Platelet Response to Avatrombopag Among Patients with Primary Immune Thrombocytopenia Who Switched from Eltrombopag or Romiplostim: the REAL-AVA 2.0 Real-World Study Presenting Author: Shruti Chaturvedi Poster presentation Session title: Poster Session 1Session date: Friday, 13 June Session time: 18:30 - 19:30 CEST Location: Poster Hall PF1239: Durability of Response to Avatrombopag Among Patients with Primary Immune Thrombocytopenia: The REAL-AVA 2.0 Real-World Study Presenting Author: Srikanth Nagalla PF1251: Clinically Meaningful Response to Avatrombopag: A Phase 3B Trial for Treatment of Children with ITP Presenting Author: Rachael F. Grace PS2231: Effectiveness and safety of avatrombopag for the treatment of adults with newly diagnosed, persistent, or chronic immune thrombocytopenia: Interim results from the phase 4 ADOPT study Presenting Author: Waleed Ghanima Poster presentation Session title: Poster Session 2Session date: Saturday, 14 June Session time: 18:30 - 19:30 CEST Location: Poster Hall PS2234: Efficacy and safety of avatrombopag for the treatment of pediatric immune thrombocytopenia in the open-label extension of a phase 3, randomized, double-blind, placebo-controlled trial Presenting Author: Rachael F. Grace PS2239: Real-World Treatment Patterns & Clinical Outcomes in Thrombopoietin Receptor Agonist Naive Patients with Immune Thrombocytopenia Treated with Avatrombopag: Interim Results from the REAL-AVA 3.0 Study Presenting Author: Sandhya Panch PS2242: Effectiveness and safety of avatrombopag for treatment of immune thrombocytopenia in older patients and those with comorbidities or prior TPO-RA exposure: Interim results from the phase 4 ADOPT study Presenting Author: María Eva Mingot-Castellano PS2244: Response to Avatrombopag Among Patients with Chronic and Persistent Primary Immune Thrombocytopenia: the REAL-AVA 2.0 Real-World Study Presenting Author: M Y Levy PS2250: Evaluation of Efficacy and Safety of Avatrombopag in Children with Immune Thrombocytopenia based on Disease Duration: Results from the Avatrombopag Phase 3-b Pediatric Trial Presenting Author: Rachael F. Grace PB3676: Baseline Correlates with Durability of Avatrombopag Response: A Phase 3B Trial for Treatment of Children with ITP Publication Only Published on May 14 at 15:30 CEST PB3684: Consistent Response to Avatrombopag across Various Baseline Characteristics: Results from the Phase 3-b Trial for the Treatment of Children with Immune Thrombocytopenia Myelofibrosis PF849: Hematologic improvement experienced by pacritinib-treated patients with myelofibrosis in real-world clinical settings Presenting Author: Michael Marrone Poster presentation Session title: Poster Session 1Session date: Friday, 13 June Session time: 18:30 - 19:30 CEST Location: Poster Hall PF1242: Efficacy of pacritinib vs momelotinib in patients with thrombocytopenic MF: a matched adjusted indicated treatment comparison Presenting Author: Koo Wilson PF1306: Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with pacritinib compared to best available therapy based on PERSIST-2 trial Presenting Author: Abiola Oladapo PS1827: Real-world effectiveness of pacritinib in patients with myelofibrosis who have concurrent thrombocytopenia and anemia Presenting Author: Raajit Rampal Poster presentation Session title: Poster Session 2 Session date: Saturday, 14 June Session time: 18:30-19:30 CEST Location: Poster Hall PS1842: Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x109/L at PAC initiation: Interim results from the MY-PAC Study Presenting Author: Doug Tremblay PS2295: Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database Presenting Author: Lucia Marasova PB3079: Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database Publication Only Published on May 14 at 15:30 CEST Paroxysmal Nocturnal Hemoglobinuria PF672: Early response in complement inhibitor naïve patients with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan in the Phase 3 PRINCE trial Presenting Author: Austin Kulasekararaj Poster presentation Session title: Poster Session 1Session date: Friday, 13 June Session time: 18:30 - 19:30 CEST Location: Poster Hall PF676: Interim analysis of the ongoing COMPLETE study on the real-world effectiveness of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria (PNH) Presenting Author: Regis Peffault de Latour PS1662: A benefit assessment of pegcetacoplan dose increase in the Phase 3 PEGASUS trial of PNH patients with difficult-to-control disease Presenting Author: Morag Griffin Poster presentation Session title: Poster Session 2Session date: Saturday, 14 June Session time: 18:30 - 19:30 CEST Location: Poster Hall PS1665: Benefit of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria irrespective of baseline transfusion status Presenting Author: Britta Höchsmann Primary Hemophagocytic Lymphohistiocytosis (pHLH) PF1036: Emapalumab in patients with primary hemophagocytic lymphohistiocytosis: Efficacy and safety outcomes from a multinational, open-label, single-arm study Presenting Author: Franco Locatelli Poster presentation Session title: Poster Session 1Session date: Friday, 13 June Session time: 18:30 - 19:30 CEST Location: Poster Hall About pegcetacoplan in rare diseases Pegcetacoplan is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, a part of the body’s immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is under investigation for rare diseases across haematology and nephrology. Pegcetacoplan is approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as EMPAVELI®/Aspaveli® in the United States, European Union, and other countries globally About Doptelet® (avatrombopag) Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure. About Zynlonta® (loncastuximab tesirine)Zynlonta® (loncastuximab tesirine) is a CD19-directed antibody drug conjugate (ADC). Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. We provide access to innovative treatments that transform life for people. Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care. We contribute to societies by improving access to treatment of rare diseases. Every day, we work actively to find better ways to understand and meet patient needs. Find out more about our business and financial performance. Here we present current and past media releases, images and videos.

临床3期免疫疗法临床结果上市批准临床1期

2025-06-03

·Pharma Patent Study

氘代策略的IP考量

近期，国内药品监管机构批准上市了两款氘代药物，分别为氘代恩杂鲁胺及吉卡西替尼（后者为莫洛替尼的氘代衍生物）。结合此前已获批的氘代丁苯那嗪、氘代多纳非尼、氘代鲁索替尼及氘可来昔替尼，及在临床上的氘代奥希替尼，氘代药物领域呈现出显著的研发与上市活跃态势。氘代修饰策略已被证实为一种有效降低新药研发风险的途径。然而，该策略在实施过程中所伴随的知识产权（IP）风险，亟需审慎评估与有效规避。本文旨在对此进行初步探讨。1. 自由实施（FTO）风险分析为规避拟开发的氘代药物落入原研药物专利保护范围的风险，需对原研专利的申请文本进行详尽分析。分析重点应包含以下两方面：取代基审查：需重点排查权利要求及说明书中是否明确将氘或氘代基团作为取代基选项予以限定。定义与涵盖范围审查：需仔细研读说明书全文，特别是定义部分，需明确原研发明是否明确声明涵盖其化合物的氘代产物，或其所定义的“氢”（H）是否包含氘（D）同位素。当前，多数原研专利申请文本即便未将氘作为具体取代基列出，亦常在定义部分明确声明其发明涵盖相应的氘代衍生物。然而，并非所有专利申请均采用此撰写策略。因此，相较于早期阶段，当前基于氘代策略进行规避设计的操作空间已显著受限。若原研专利文本中已明确记载了相关氘代物，则当原研专利权人发现竞争者开发氘代产品时，极有可能基于其专利权主张直接侵权，或在获得涵盖氘代产物的权利要求授权后提起侵权之诉。Incyte Pharmaceuticals 针对 Concert Pharmaceuticals 的策略即为此类风险的典型案例佐证。2. 专利授权可能性考量氘代药物自身获得专利权授权至关重要。此考量不仅源于保护自身创新成果的需求，更在于降低未来潜在的等同侵权风险。值得关注的是，目前各国专利审查机构对于氘代衍生物的可专利性审查标准相对宽松。然而，若现有技术已明确揭示特定化合物的特定位置为氘代修饰的热点（即该位点的氘代已被证明能带来显著代谢优势），则针对该位点进行氘代所形成的新化合物，其创造性高度及授权前景将面临严峻挑战，需予以高度重视。3. 市场竞争策略考量在氘代药物的开发决策中，除知识产权风险外，市场竞争格局亦为关键考量因素。开发者需审慎评估氘代药物上市后，其市场独占期是否与原研药物仿制药的上市时间存在重叠，以避免陷入激烈的同质化竞争，氘代产品有显著优势的则另当别论。好像有氘代茅台！

专利侵权

2025-04-30

·药时空

GSK Q1：全年营收超 95 亿美元，肿瘤收入大涨 53%

4 月 30 日，葛兰素史克（GSK）发布 2025 年 Q1 财报，全年营收 75.16 亿英镑（95.04 亿美元），同比增长 4%（按固定汇率计算，下同）。研发投入 14.62 亿英镑（18.49 亿美元），同比增长 3%。来源：GSK 官网（下同）GSK 的业务主要分为特药（Specialty Medicines）、疫苗（Vaccines）以及普药（General Medicines）三个版块，2025 年 Q1 分别贡献了 29.33 亿英镑（37.10 亿美元，+17%）、20.95 亿英镑（26.48 亿美元，-6%）、24.88 亿英镑（31.46 亿美元，稳定）的业绩收入。具体来说，特药方面，GSK 在HIV、呼吸/免疫和肿瘤疾病领域分别斩获了 17 亿英镑（+7%）、8 亿英镑（+28%）、4 亿英镑（+53%），增长迅猛，尤其是肿瘤产品，已经成为 GSK 业绩新的增长点。GSK 肿瘤板块增长主要得益于骨髓纤维化贫血患者药物 Ojjaara/Omjjara（莫洛昔尼，2023 年 9 月上市）的推出，以及 PD-1 单抗 Jemperli（Dostarlimab，2021 年 4 月上市）新适应症的拓展和市场渗透程度的增加，两款产品 2025 年 Q1 销售额分别为 1.12 亿英镑和 1.74 亿英镑，2 款产品的同比增长率均大于 100%。呼吸/免疫领域，Nucala （美泊利珠单抗）和 Benlysta（贝利尤单抗）分别为 GSK 贡献了 4.44 亿英镑（+21%）和 3.59 亿英镑（+39%）的销售额。HIV 领域，GSK 手握长效产品，市场表现不俗，销售额持续增长。其中 Cabenuva（卡替拉韦+利匹韦林）、Apretude （卡替拉韦）和 Dovato （多替拉韦+拉米夫定）分别获得了 2.94 亿英镑（+38%）、0.89 亿英镑（+63%）和 5.7 亿英镑（+19%）的收入。疫苗方面，GSK 产品销售陷入疲软期，收入 20.95 亿英镑，仅脑膜炎疫苗实现了两位数增长，被寄予厚望的 RSV 疫苗 Arexvy 遭受腰斩。Arexvy 在 2023 年 5 月首次获 FDA 批准，随后又相继在欧盟、日本获批上市。作为全球首款 RSV 疫苗，Arexvy 在上市第一年便成功斩获了 15.43 亿美元的销售额。但 2024 年，由于需求下降，该产品全球销售额下滑 51%，仅有 5.90 亿英镑的收入。2025 年 Q1 销售额达 0.78 亿英镑，同比下滑 57%。Shingrix 是一款重组带状疱疹疫苗，2024 年以 33.64 亿英镑（+1%）的收入继续稳坐全球疫苗大品种的宝座。2025 Q1 该产品的销售额为 8.67 亿英镑，同比下滑 7%。脑膜炎疫苗 Meningitis（包括 Bexsero 和 Menveo ）增长强劲，为 GSK 疫苗板块注入了新的动力，2025 年 Q1 斩获了 3.5 亿英镑的销售额，同比增长 20%。GSK 在财报中披露，预计 2025 年 FDA 将批准 5 项主要新产品：2025 年第一季度批准：Penmenvy，脑膜炎疫苗；Blujepa，用于治疗尿路感染的首创抗生素预计进一步获批的药物包括：Nucala（慢性阻塞性肺病）；Blenrep（多发性骨髓瘤）；以及 Depemokimab（严重哮喘和鼻息肉）识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

财报疫苗上市批准

100 项与莫莫替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10358 D10889	莫莫替尼	-	DB11763

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
原发性血小板增多症后骨髓纤维化	加拿大	GSK Plc	2024-11-12
真性红细胞增多症后骨髓纤维化	加拿大	GSK Plc	2024-11-12
原发性骨髓纤维化	加拿大	GSK Plc	2024-11-12
贫血	英国	GSK Plc	2024-01-30
骨髓病性贫血	欧盟	GlaxoSmithKline Trading Services Ltd.	2024-01-25
骨髓病性贫血	冰岛	GlaxoSmithKline Trading Services Ltd.	2024-01-25
骨髓病性贫血	列支敦士登	GlaxoSmithKline Trading Services Ltd.	2024-01-25
骨髓病性贫血	挪威	GlaxoSmithKline Trading Services Ltd.	2024-01-25
脾肿大	欧盟	GlaxoSmithKline Trading Services Ltd.	2024-01-25
脾肿大	冰岛	GlaxoSmithKline Trading Services Ltd.	2024-01-25
脾肿大	列支敦士登	GlaxoSmithKline Trading Services Ltd.	2024-01-25
脾肿大	挪威	GlaxoSmithKline Trading Services Ltd.	2024-01-25
骨髓纤维化	美国	GlaxoSmithKline LLC	2023-09-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血小板减少症	临床3期	美国	Sierra Oncology, Inc.	2014-06-19
血小板减少症	临床3期	加拿大	Sierra Oncology, Inc.	2014-06-19
血小板减少症	临床3期	法国	Sierra Oncology, Inc.	2014-06-19
血小板减少症	临床3期	德国	Sierra Oncology, Inc.	2014-06-19
血小板减少症	临床3期	以色列	Sierra Oncology, Inc.	2014-06-19
血小板减少症	临床3期	意大利	Sierra Oncology, Inc.	2014-06-19
血小板减少症	临床3期	西班牙	Sierra Oncology, Inc.	2014-06-19
血小板减少症	临床3期	英国	Sierra Oncology, Inc.	2014-06-19
转移性胰腺导管腺癌	临床3期	美国	Sierra Oncology, Inc.	2014-06-02
骨髓增生异常综合征	临床2期	美国	GSK Plc	2025-06-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SIMPLIFY-1 (EHA2025)	临床3期	贫血 \| 骨髓纤维化	-	Momelotinib	觸窪醖壓鏇觸夢艱繭齋(鹹鬱鑰繭衊鬱淵淵膚醖) = OS was prolonged in patients achieving TI ± SVR35 at week 24 with momelotinib vs those who achieved neither endpoint 構積餘艱鬱窪鹽鹹壓窪 (鬱餘膚蓋遞餘醖糧膚顧 )	积极	2025-05-14
				Ruxolitinib
SIMPLIFY-1 and MOMENTUM (EHA2025)	临床3期	贫血 \| 骨髓纤维化	215	Momelotinib	繭蓋衊壓廠廠製膚鹹齋(膚艱襯衊網襯蓋夢鹹憲) = 觸夢鏇廠觸糧憲糧窪選鬱築窪鏇廠膚淵衊廠醖 (繭齋製觸簾鹹繭糧製顧 ) 更多	积极	2025-05-14
				Ruxolitinib	繭蓋衊壓廠廠製膚鹹齋(膚艱襯衊網襯蓋夢鹹憲) = 鬱鏇範觸簾壓糧鬱網窪鬱築窪鏇廠膚淵衊廠醖 (繭齋製觸簾鹹繭糧製顧 ) 更多
ASH2024	N/A	-	-	Momelotinib	鏇淵遞衊網繭蓋構構餘(構餘糧鹹積餘構獵構繭): HR = 0.373 (95% CI, 0.297 ~ 0.469), P-Value = <.001	-	2024-12-08
				Best Available Therapy (BAT)
ASH2024	N/A	骨髓纤维化	-	Momelotinib 200mg	壓願選觸糧淵壓壓鬱餘(顧鑰齋顧範夢繭選構窪) = 願憲鬱蓋醖廠窪範構艱範醖鑰網選廠壓鏇製鹽 (齋餘淵遞繭糧觸淵鏇齋 ) 更多	-	2024-12-07
NCT04173494 \| NCT02101268 \| NCT02515630 \| NCT01969838 (SIMPLIFY-1 \| SIMPLIFY-2 \| MOMENTUM, Pubmed \| Clin Lymphoma Myeloma Leuk)	临床2/3期	骨髓纤维化 JAK inhibitor-naive	-	Momelotinib	願選醖窪觸淵築選鬱遞(範簾淵構衊範夢築築膚) = 齋構夢蓋選製壓願築積製構糧構觸鏇遞積顧鑰 (糧鏇艱餘獵鏇憲鑰餘衊 )	积极	2024-10-01
				Ruxolitinib	願選醖窪觸淵築選鬱遞(範簾淵構衊範夢築築膚) = 繭醖餘顧膚築艱鏇範艱製構糧構觸鏇遞積顧鑰 (糧鏇艱餘獵鏇憲鑰餘衊 )
SOHO2024	N/A	骨髓纤维化	-	Momelotinib	獵膚膚範艱鬱觸衊簾鬱(鏇廠選壓艱蓋膚網願齋) = Common reasons for stopping MOM/PAC were adverse events (n=3; AKI, diarrhea, rash) 餘糧鏇蓋醖鬱願選襯餘 (繭壓鏇鬱醖顧餘膚艱製 ) 更多	-	2024-09-04
				Pacritinib
SOHO2024	N/A	骨髓纤维化	-	Momelotinib (MMB)	襯獵蓋築構壓鬱衊鬱襯(鬱餘夢簾選製窪觸網獵) = 蓋夢艱構網窪蓋淵襯觸網積壓鏇蓋範製膚簾鏇 (窪膚範製築網範遞齋願 )	-	2024-09-04
				Pacritinib (PAC)	襯獵蓋築構壓鬱衊鬱襯(鬱餘夢簾選製窪觸網獵) = 築願糧觸獵繭鑰鹽積願網積壓鏇蓋範製膚簾鏇 (窪膚範製築網範遞齋願 )
MPN-085 (SOHO2024)	临床3期	贫血 \| 骨髓纤维化	480	Momelotinib (Hemoglobin improvement)	觸繭選艱簾觸鏇醖淵網(鹹艱夢積遞憲製蓋蓋鏇) = 廠鏇範鑰鏇選觸蓋膚淵淵鏇淵築鹹糧醖簾網膚 (窪蓋廠襯觸鹽網鹽鹹獵 ) 更多	积极	2024-09-04
				Momelotinib (No hemoglobin improvement)	觸繭選艱簾觸鏇醖淵網(鹹艱夢積遞憲製蓋蓋鏇) = 築鏇鏇齋構襯蓋築鏇鹹淵鏇淵築鹹糧醖簾網膚 (窪蓋廠襯觸鹽網鹽鹹獵 ) 更多
SOHO2024	N/A	-	-	Ruxolitinib	鑰鹹願艱鹽夢鑰壓壓淵(鑰鑰襯範選衊艱鬱範鑰) = 鑰構餘獵製構衊範遞範憲艱憲醖窪窪齋壓簾淵 (顧淵艱範鏇憲壓襯獵網, 1.0)	-	2024-09-04
NCT02101268 (SIMPLIFY-2, Pubmed)	临床3期	贫血 \| 骨髓纤维化	156	Momelotinib	膚繭壓蓋構鏇遞鑰襯夢(鹽願遞觸製簾廠鏇廠艱) = were generally higher in both subgroups with momelotinib 鏇壓簾網遞願鹽憲淵鏇 (顧獵鏇醖齋選夢願製遞 )	积极	2024-07-11
				Continued Ruxolitinib or Best Available Therapy